Medicure Announces Grant of Stock Options

Rhea-AI Summary

Medicure Inc. (OTC: MCUJF) announced the grant of stock options to certain officers, allowing the purchase of 90,000 common shares at $1.10 each. The options, which vest immediately, can be exercised over five years and require TSX Venture Exchange approval. Medicure is focused on the U.S. cardiovascular market and markets AGGRASTAT® and ZYPITAMAG®. The company's operations include Marley Drug, a North Carolina pharmacy providing an Extended Supply mail order program across many states.

Positive

• Grant of stock options to officers could align management interests with shareholder value.
• Immediate vesting of options may enhance executive motivation.

Negative

• None.

WINNIPEG, MB, July 30, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Company's current stock option plan.  The grant of Options is subject to the approval of the TSX Venture Exchange.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^® (tirofiban hydrochloride) injection and ZYPITAMAG^® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley"), a pharmacy located in North Carolina that offers an Extended Supply mail order drug program serving 49 states, Washington D.C. and Puerto Rico. Marley is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT^®, refer to the full Prescribing Information. For additional information about ZYPITAMAG^®, refer to the full Prescribing Information.

To be added to Medicure's e-mail list, please visit:     
http://medicure.mediaroom.com/alerts

View original content:https://www.prnewswire.com/news-releases/medicure-announces-grant-of-stock-options-301344839.html

SOURCE Medicure Inc.

FAQ

What is the purpose of Medicure's recent stock options grant?

The stock options grant aims to align management incentives with shareholder value by allowing officers to purchase shares at a set price.

How many stock options did Medicure grant?

Medicure granted a total of 90,000 stock options to certain officers.

What is the exercise price for Medicure's stock options?

The exercise price for the stock options is set at $1.10 per common share.

What is the vesting schedule for the stock options granted by Medicure?

The stock options granted by Medicure vest immediately.

What is Medicure's focus in the pharmaceutical market?

Medicure is focused on the development and commercialization of pharmaceuticals for the U.S. cardiovascular market.